Open Biosystems’ shRNAmir Technology Adopted by Renowned Cancer Centers
News Dec 20, 2005
Open Biosystems, Inc. has announced that four renowned cancer centers have adopted the company’s short hairpin RNA (shRNAmir) technology to aid in the identification of advanced cancer treatment options.
Duke University, the National Institutes of Health’s National Cancer Institute, Lee Moffitt Cancer Center and Fox Chase Cancer Center have invested in human and/or mouse shRNAmir whole genome libraries to accelerate research related to cancer biology and drug discovery.
Open Biosystems’shRNAmir libraries are designed to harness a cell’s natural RNAi pathway, shRNAmir expression results in superior knockdown and tighter targeting of the specific gene being studied.
Cancer researchers can use the shRNAmir libraries to screen entire genomes in a high throughput manner, identifying tumor suppressors and possible drug targets.
As a result, cancer researchers are adopting the shRNAmir technology to identify specific genes that suppress tumor growth and the spread of cancer.
"The ability to perform loss of function screens in mammalian cells is revolutionizing the way we study biology," said Peter Adams, Member, Fox Chase Cancer Center, Philadelphia.
"We selected Open Biosystems’ shRNA library because we view the technology as the best available on the market today and the company has been very responsive to our specific needs and requirements for information and support."
"Open Biosystems’ shRNAmir libraries enable us to manipulate gene expression and probe gene function on a whole-genome scale, accelerating a wide range of basic and translational research programs, including cancer research," said Thomas Burke, Ph.D., General Manager of Technologies at the Duke Institute for Genome Sciences & Policy.
"Rather than spending limited time and resources designing, constructing and characterizing RNAi reagents, our researchers can now select shRNAmir clones targeting genes of interest, and place these into functional assays accelerating research that may lead to advanced treatment options for cancer."
"Distinguished cancer centers have turned to Open Biosystems’ shRNAmir technology for efficient and versatile gene silencing options for cancer research," said Troy Moore, Chief Technology Officer at Open Biosystems.
"Gene silencing using RNAi is an effective technique whose potential has just begun to be tapped."
"Our shRNAmir libraries will greatly simplify discovery and validation of tumor suppressor function as well as the establishment of animal models for cancer."
"As a growing number of researchers and scientists recognize the value and impact of gene silencing for the treatment of disease, we will continue to partner with leading organizations to further this area of research."
Calidi Biotherapeutics, Inc. Announces its Corporate Vision in Groundbreaking Cancer Drug DevelopmentNews
Calidi Biotherapeutics, Inc., formerly StemImmune, Inc., a clinical‐stage biotherapeutics company at the forefront of oncolytic virus-based immunotherapies for cancer, announced a focused effort to advance its oncolytic virus drug development.READ MORE
Genetic Diversity Helps Protect Against DiseaseNews
Why do populations have genetic diversity when 'Survival of the Fittest' suggests that only one gene pool should thrive? It's a question that is hard to answer experimentally. A new study looking at evolutionary change in real time in tiny fungal parasites may provide a solution.